Journal article
Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease
A Rembach, NG Faux, AD Watt, KK Pertile, RL Rumble, BO Trounson, CJ Fowler, BR Roberts, KA Perez, QX Li, SM Laws, K Taddei, S Rainey-Smith, JS Robertson, M Vandijck, H Vanderstichele, KJ Barnham, KA Ellis, C Szoeke, L MacAulay Show all
Alzheimer S and Dementia | Published : 2014
Abstract
Background: A practical biomarker is required to facilitate the preclinical diagnosis of Alzheimer's disease (AD). Methods: Plasma amyloid beta (Aβ)1-40, Aβ1-42, Aβn-40, and Aβn-42 peptides were measured at baseline and after 18 months in 771 participants from the Australian Imaging Biomarkers and Lifestyle (AIBL) study of aging. Aβ peptide levels were compared with clinical pathology, neuroimaging and neuropsychological measurements. Results: Although inflammatory and renal function covariates influenced plasma Aβ levels significantly, a decrease in Aβ1-42/Aβ1-40 was observed in patients with AD, and was also inversely correlated with neocortical amyloid burden. During the 18 months, plasma..
View full abstractRelated Projects (1)
Grants
Funding Acknowledgements
Core funding for the study was provided by CSIRO, which was supplemented by in-kind contributions from the study partners (aibl.csiro.au). The research was also supported by the Science Industry and Endowment Fund (sief.org.au) and the National Health and Medical Research Council (NHMRC) via the Dementia Collaborative Research Centres program (DCRC2). The Mental Health Research Institute acknowledges the funding support from the Victorian government's Operational Infrastructure Support program. Pfizer International has contributed financial support to assist with analysis of blood samples and to further the Australian Imaging Biomarkers and Lifestyle research program. Alzheimer's Australia (Victoria and Western Australia) assisted with promotion of the study and the screening of telephone calls from volunteers. We thank Innogenetics-Fujirebio (Ghent, Belgium) for partially supporting the costs of the INNO-BIA immunoassay kits used in this study.